Lynparza FDA Approved, in Combination With Abiraterone and Prednisone (or Prednisolone), for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutation

JHOP - June 2023 Vol 13, No 3 - FDA Oncology Update
NEW INDICATIONS

On May 31, 2023, the FDA approved a new indication for olaparib (Lynparza; AstraZeneca Pharmaceuticals), a poly (ADP-ribose) polymerase inhibitor, in combination with abiraterone and prednisone (or prednisolone), for adults with deleterious or suspected deleterious BRCA mutation–positive, metastatic, castration-resistant prostate cancer (CRPC), as determined by an FDA-approved test.

Olaparib was previously approved as monotherapy for patients with metastatic CRPC and deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutation–positive, metastatic CRPC whose disease progressed after previous treatment. The drug also has received various approvals for the treatment of ovarian, breast, and pancreatic cancers.

The current FDA approval was based on results from the phase 3 PROpel clinical trial (NCT03732820) of 796 patients with metastatic CRPC. Patients were randomized 1:1 to olaparib with abiraterone or to placebo with abiraterone, and received prednisone or prednisolone. To be included in the trial, patients had to have a previous orchiectomy or, if not, had to have received gonadotropin-releasing hormone (GnRH) analogs. Patients were excluded if they had received systemic therapy for metastatic CRPC, but previous treatment with docetaxel for metastatic hormone-sensitive prostate cancer was allowed. Randomization was stratified by previous docetaxel treatment and site of metastases. Retrospective testing for BRCA mutational status, with the FoundationOne CDx and FoundationOne Liquid CDx tests, was performed on all available clinical samples.

The major efficacy measure was investigator-assessed radiologic progression-free survival (PFS), with overall survival (OS) as an additional end point.

Patients who received olaparib plus abiraterone had a significant improvement in radiologic PFS compared with patients who received placebo plus abiraterone in the intent-to-treat (ITT) population. In the 85 patients with a BRCA mutation (11% of the ITT population), an exploratory subgroup analysis revealed a median radiologic PFS that was not reached with olaparib plus abiraterone compared with 8 months (95% confidence interval [CI], 6-15) with placebo plus abiraterone (hazard ratio [HR], 0.24; 95% CI, 0.12-0.45). In this subgroup, the OS HR was 0.3 (95% CI, 0.15-0.59). The subgroup of patients without a BRCA mutation (n=711; 89% of ITT population) had a radiologic PFS HR of 0.77 (95% CI, 0.63-0.96) and an OS HR of 0.92 (95% CI, 0.74-1.14), suggesting that the radiologic PFS improvement in the ITT population was mainly attributable to patients with the BRCA mutation.

The most common (≥10%) adverse events with olaparib plus abiraterone were anemia (48%), fatigue (38%), nausea (30%), diarrhea (19%), decreased appetite (16%), lymphopenia (14%), dizziness (14%), and abdominal pain (13%). A total of 72 (18%) patients needed ≥1 blood transfusions and 46 (12%) needed multiple transfusions.

“Preventing or delaying radiographic progression or death is an important clinical end point in assessing cancer treatment and is very important to patients, their caregivers, and their families,” said Andrew Armstrong, MD, MSc, of Duke Cancer Institute, Durham, NC, and a trial investigator. “The PROpel results showed the Lynparza combination demonstrated a notable clinically meaningful benefit that should rapidly be considered as the standard-of-care treatment for patients with BRCA-mutated metastatic castration-resistant prostate cancer.”

A twice-daily 300-mg dose of olaparib is recommended, taken orally with or without food. For abiraterone, the recommended dose is 1000 mg orally once daily. Abiraterone should be given twice daily with 5 mg of oral prednisone or prednisolone. In addition, patients should receive a GnRH analog concurrently or should have had a bilateral orchiectomy.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: